Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182343
Title: | Impact of SARS-CoV-2 pandemic on vascular liver diseases |
Author: | Baiges Aznar, Anna Cerda, Eira Amicone, Caroline Tellez, Luis Alvarado Tapias, Edilmar Puente, Angela Fortea, Jose Ignacio Llop, Elba Rocha, Filipa Orts, Lara Ros Fargas, Olivia Vizcarra, Pamela Zekrini, Kamal Amara Lounes, Ould Touati, Ghiles Jimenez, Natalia Serrano, Maria Jose Falgà, Àngels Magaz Martínez, Marta Olivas, Pol Betancourt, Fabian Pérez Campuzano, Valeria Turon, Fanny Payancé, Audrey Goria, Odile Rautou, Pierre Emmanuel Hernández Gea, Virginia Villanueva, Candid Albillos, Agustín Plessier, Aurélie García Pagán, Juan Carlos |
Keywords: | SARS-CoV-2 COVID-19 Malalties vasculars Malalties del fetge SARS-CoV-2 COVID-19 Vascular diseases Liver diseases |
Issue Date: | 26-Dec-2021 |
Publisher: | W.B. Saunders |
Abstract: | Vascular liver diseases (VLD) are represented mainly by portosinusoidal vascular disease (PSVD), non-cirrhotic splanchnic vein thrombosis (SVT) and Budd Chiari syndrome (BCS). It is unknown whether patients with VLD constitute a high-risk population for complications and greater COVID-19-related mortality from SARS-CoV-2 infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLD, as well as to assess its impact on hepatic decompensation and survival.This is a observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLD between March 2020-March 2021 comparing with the general population (GP). Patients from Spain (5 centers, n = 493) and France (1 center, n = 475) were included.Nine hundred and sixty-eight patients were included: 274 PSVD, 539 SVT and 155 BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 PSVD, 77 SVT and 8 BCS. The prevalence of SARS-CoV-2 infection in PSVD (19%) and SVT (14%) was significantly higher than in GP (6.5%, p < 0.05), while it was very similar in BCS (5%). In terms of infection severity, patients with VLD also presented a higher need of hospital admission (14% vs 7.3%, p<0.01), ICU admission (2% vs 0.7%, p< 0.01) and mortality (4% vs 1.5%, p < 0.05) than GP. Previous history of ascites (50% vs 8%, p < 0.05) and post-COVID-19 hepatic decompensation (50% vs 4%, p < 0.05) were associated to COVID-19 mortality.PSVD and SVT patients could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Note: | versió postprint del document publicat a: https://doi.org/10.1016/j.cgh.2021.12.032 |
It is part of: | Clinical Gastroenterology And Hepatology, 2021 |
URI: | http://hdl.handle.net/2445/182343 |
Related resource: | https://doi.org/10.1016/j.cgh.2021.12.032 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_9295622_pre-proof_-_impact_of_sars-cov-2_pandemic_on_vascular_liver_deseases.pdf | 1.26 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License